Vaxinano

Vaxinano is a biotechnology company specializing in preclinical and drug development for humans. Vaxinano positions itself as the first company able to develop inactivated vaccines without nasal adjuvants, with evidence of effectiveness against influenza and COVID-19. Vaxinano's experimental vaccines target toxoplasmosis and tuberculosis, and Vaxinano is developing antibacterial, antiviral, and antiparasitic vaccines. In addition to vaccine development, the company also conducts contract research and assists its clients with nanomedicine R&D.